MAZE
Maze Therapeutics, Inc.
One of a new wave of genetics-driven drug developers, Maze Therapeutics reads human DNA for genetic quirks that protect some people from disease, then builds medicines that copy those protective effects. Founded in 2019 by scientists including CRISPR researcher Jonathan Weissman, the South San Francisco firm grew out of academic discoveries about how certain gene variants shield carriers from illness. Its name hints at the mission: threading the winding maze of the human genome for clues.
CUSIP: 578784100HealthcareUS1 holder
Recent Activity
2025Q4
1 buy
+222.3K shares(+40.8%)
+222.3K shares(+40.8%)
2025Q3
1 buy
+545.1K shares
+545.1K shares